NEWS HIGHLIGHTSMedia Articles Related to Methyldopa
High Blood Pressure (Hypertension) Quiz: Symptoms, Signs & Causes Source: MedicineNet Facial Nerve Problems Specialty [2017.09.19] Title: High Blood Pressure (Hypertension) Quiz: Symptoms, Signs & Causes Category: MedicineNet Quiz Created: 2/9/2011 12:00:00 AM Last Editorial Review: 9/19/2017 6:02:11 PM
Pulmonary Hypertension (Symptoms, Treatment Medications, Life Expectancy) Source: MedicineNet Congenital Heart Disease Specialty [2017.07.26] Title: Pulmonary Hypertension (Symptoms, Treatment Medications, Life Expectancy) Category: Diseases and Conditions Created: 12/31/1997 12:00:00 AM Last Editorial Review: 7/26/2017 12:00:00 AM
High Blood Pressure (Hypertension) Source: MedicineNet Polycystic Ovary Specialty [2017.03.31] Title: High Blood Pressure (Hypertension) Category: Symptoms and Signs Created: 1/15/2014 12:00:00 AM Last Editorial Review: 3/31/2017 12:00:00 AM
Portal Hypertension Source: MedicineNet nitroglycerin Specialty [2016.09.06] Title: Portal Hypertension Category: Diseases and Conditions Created: 1/31/2005 12:00:00 AM Last Editorial Review: 9/6/2016 12:00:00 AM
Picture of Hypertension Source: MedicineNet betaxolol ophthalmic Specialty [2014.12.09] Title: Picture of Hypertension Category: Images Created: 2/3/2011 12:00:00 AM Last Editorial Review: 12/9/2014 12:00:00 AM
Published Studies Related to Methyldopa
Single dose bioequivalence study of alpha-methyldopa tablet formulations using a modified HPLC method. [2010] BACKGROUND AND OBJECTIVE: The purpose of the present study was to compare the bioavailability of a new methyldopa (CAS 555-30-6) tablet formulation with that of a reference formulation in 12 healthy male subjects using a modified HPLC method... CONCLUSION: A rapid and reliable HPLC method with fluorescence detector was developed to analyze alpha-methyldopa in human plasma. Based on the obtained results the test formulation of alpha-methyldopa is bioequivalent to the reference formulation.
Methyldopa for primary hypertension. [2009.10.07] CONCLUSIONS: Methyldopa lowers blood pressure to varying degrees compared to placebo for patients with primary hypertension. Its effect on clinical outcomes, however, remains uncertain.
A rapid high performance liquid chromatographic determination of methyldopa in human serum with fluorescence detection and alumina extraction: application to a bioequivalence study. [2006.03.07] A simple and ultra rapid high performance liquid chromatographic (HPLC) method coupled with alumina extraction and fluorescence detection was described for determination of methyldopa in human serum. The drug and an internal standard were adsorbed onto alumina and eluted using acidic methanol... This method has been used in a randomized crossover bioequivalence study of two different methyldopa preparations in 24 healthy volunteers.
Methyldopa supplement for resistant essential hypertension: a prospective randomized placebo control crossover study. [2003.12] CONCLUSION: The addition of methyldopa to the optimal medical therapy contributed to the improvement of BP control among patients with resistant HT.
Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. [2003] The objective was to assess the single-dose pharmacokinetics of clonazepam following i.m., p.o...
Clinical Trials Related to Methyldopa
A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy [Terminated]
High blood pressure (BP) before pregnancy is called chronic hypertension (CHTN), and is
associated with an increased risk of development of pregnancy related high BP called
preeclampsia, preterm delivery, decreased growth of the fetus, fetal death, premature
separation of the placenta from the uterus resulting in damage to the fetus and cesarean
delivery. Longer duration and severity of CHTN in pregnancy leads to worse outcomes for the
mother and the fetus. Treatment of mild CHTN in pregnancy does not improve these outcomes,
and therefore, medications to lower BP are used for moderate to severe hypertension. To date
the literature on the medications used in pregnancy is extremely limited.
Methyldopa is used as a first choice medicine for CHTN in pregnancy. It acts on the central
nervous system (CNS) by relaxation of the blood vessels leading to a decrease in BP. It does
not decrease the blood flow to the uterus, placenta, or the fetus (4). Methyldopa is a weak
antihypertensive medicine given three or four times a day and frequently needs changes in
the dose or may require an additional medication to control BP. This may lead to a greater
chance of non compliance. Another option is Clonidine which is an effective antihypertensive
treatment and is available in many forms (oral, parenteral, and transdermal.) It acts on the
maternal CNS. Clonidine is not associated with teratogenic or neonatal side effects.
Transdermal clonidine (catapres-TTSĀ®) is a preparation of clonidine hydrochloride that can
be released and absorbed transdermally over a 7-day period.
The study will determine differences in compliance between the two antihypertensive
regimens- oral methyldopa and Catapres-TTS, comparisons of patient tolerability, compliance
and adequacy of BP control, as well as provide information on an alternate option for BP
control.
Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes [Recruiting]
Type 1 Diabetes is an autoimmune condition in which segments of the immune system cause the
destruction of insulin producing cells in the pancreas, leaving individuals with an impaired
ability to control blood glucose levels. Currently there is no cure for Type 1 Diabetes and
the treatments involve lifelong insulin administration and careful monitoring of blood
glucose levels. Long-term complications like cardiovascular disease, nerve damage, and
retina damage, may result. Previous studies have shown that improvement in the control of
blood glucose can reduce the risks from these long-term complications. Residual insulin
production, typically within the first few years following diagnosis, helps to reduce an
individual's need to supplement insulin by injection or pump. This effect helps in
maintaining the body's ability to regulate blood glucose levels and reducing the needs of
external insulin.
Methyldopa, or Aldomet, has been approved by the Food and Drug Administration and is
commonly used to treat high blood pressure. This drug has been approved for several decades
and has been shown to be safe and effective. This drug has been identified by the researcher
to be able to block the communication between two important types of immune cells; which
play a critical role in the autoimmune processes of Type 1 Diabetes. The investigators
hypothesize that Methyldopa, over a 6 week treatment period, will block this communication
and possibly slow down the destruction of insulin producing cells. The investigators hope to
assess the appropriate and safe dose to achieve this effect, along with the drug's ability
to maintain insulin production and blood glucose control.
Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia [Completed]
The present study examined the effects of Methyldopa on uterine artery diameter, uterine
artery blood flow, umbilical artery and fetal middle-cerebral artery in patients with
Preeclampsia, using Doppler ultrasound.
Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy [Not yet recruiting]
This is a pragmatic, open-label, randomised control trial of three oral anti-hypertensive
regimens for women with severe hypertension in pregnancy. Women presenting with severe
hypertension in pregnancy in two hospitals in Nagpur, India will be randomised to one of
three oral regimens: nifedipine, labetalol or methyldopa. This trial will compare the
efficacy, safety and side effects of these three oral regimens for management of
hypertension in pregnant women. The investigators hypothesize that nifedipine treatment of
severe hypertensive parturient women is more effective than treatment with labetalol or
methyldopa in controlling high blood pressure within six hours.
Autonomic Nervous System and Chronic Fatigue Syndrome [Active, not recruiting]
The investigators propose to test the hypothesis that the sympathetic nervous system
contributes to the cardiovascular and inflammatory abnormalities present in the chronic
fatigue syndrome (CFS) and, in particular in the subset of patients characterized by
postural tachycardia syndrome (POTS). CFS and POTS are seen mostly in otherwise normal
young women, and are the cause of significant disability. A substantial proportion of
patients referred for evaluation of POTS met diagnostic criteria for CFS and, conversely, a
subset of patients referred for treatment for CFS have POTS. The investigators hypothesize
that sympathetic activation underlies the pathophysiology of patients in whom CFS and POTS
overlap (CFS-P).
Reports of Suspected Methyldopa Side Effects
Maternal Exposure During Pregnancy (20),
Foetal Exposure During Pregnancy (13),
Premature Baby (10),
Premature Labour (9),
Hypertension (9),
Nausea (8),
LOW Birth Weight Baby (6),
Talipes (6),
Blood Pressure Increased (6),
Orthostatic Hypotension (5), more >>
|